Cardiogen
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Cardiogen is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Arg (AEDR). It belongs to the family of short “peptide bioregulators” developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, each of which is associated with a particular tissue — in this case, the heart.
It is most often discussed in the context of cardiovascular aging, where it has been studied for proposed effects on cardiomyocyte metabolism and the regulation of heart-related genes.
Most of the evidence to date comes from cell-culture and animal work, much of it from a single research group. Independent human clinical data is limited, and Cardiogen is not approved by any major regulator for therapeutic use.
How it works
The Khavinson bioregulator hypothesis proposes that very short peptides can enter cells, reach the nucleus, and interact with specific regions of DNA in a tissue-selective way — nudging a tissue’s own genes rather than acting like a hormone. Applied to Cardiogen, researchers have suggested the AEDR sequence may influence transcription of genes involved in cardiomyocyte function and stress response.
This mechanism is an active research hypothesis rather than an established pathway, and the concentration of intact peptide reaching cardiac tissue after administration has not been well characterized in humans.
Reported benefits
- Support for cardiomyocyte metabolism and cardiac cell function (preclinical data)
- Modulation of heart-related gene expression in laboratory models
- Interest as a candidate in research on cardiovascular aging
These are reported and studied effects from preclinical work, not guaranteed outcomes in people.
Considerations & side effects
Because rigorous human trials are lacking, the safety profile of Cardiogen is not well characterized, and long-term effects are unknown. As with other injectable research peptides, reported issues are generally mild and localized, such as injection-site irritation.
Product purity varies widely in the research-chemical market, and much of the supporting evidence comes from a single research lineage without broad independent replication. Cardiogen is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is Cardiogen?
A synthetic tetrapeptide (Ala-Glu-Asp-Arg, or AEDR) from the family of Khavinson peptide bioregulators, studied in preclinical models for effects on cardiac tissue and cardiovascular aging.
Is Cardiogen FDA-approved?
No. Cardiogen is not approved by the FDA or any major regulator for human therapeutic use, and is sold for research purposes only.
What does 'bioregulator' mean here?
It refers to a class of very short peptides proposed to act as tissue-specific regulators of gene expression, rather than as hormones or receptor agonists. This remains a research hypothesis.
How strong is the evidence for Cardiogen?
Limited. The available data is largely preclinical (cell culture and animal models) and concentrated in a single research lineage, with little independent replication and no established human clinical evidence.
References
Related compounds
An oral Khavinson peptide bioregulator (peptide complex A-3) targeting blood vessels and vascular tissue. Taken in capsule courses to support cardiovascular and blood-vessel health.
KED tripeptide vascular bioregulator. Supports endothelial health and vascular function. Studied for cardiovascular aging and vascular integrity.
An oral Khavinson peptide bioregulator (peptide complex A-8) targeting the pineal gland — the oral-capsule analog to the injectable Epithalon lineage. The most-studied compound in the Khavinson framework, tied to melatonin, circadian rhythm, and anti-aging research.